Cambridge, MA – November 23, 2009 – Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity ...

Methods used for the generation of the conditional IDH1(R132H) KI mouse ... cytosines were annotated to the nearest RefSeq gene and pathway analysis performed using the Ingenuity Pathway Analysis ...

Researchers have uncovered a gene that is overexpressed in mutated IDH1. Studies in human cells and a novel mouse model both show that this gene, called ZMYND8, plays a critical role in the ...

but these tumors do often share a common feature – over 70 percent of low-grade gliomas have a single gene mutation affecting an enzyme called isocitrate dehydrogenase 1 (IDH1). This IDH1 ...

The current classification scheme uses molecular alterations, particularly IDH1.R132H, to stratify lesions into distinct prognostic groups. Currently, neuroimaging followed by tissue biopsy ...

A new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Astrocytomas ...

Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00 The ...

Ivosidenib seeks to disrupt the action of the mutated IDH1 gene. In results presented by Dr. Pollyea at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, 41.9 percent of 258 ...

Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with relapsed or ...

IDH1 and IDH2 mutants use the latter to generate the oncogenic metabolite R-2-hydroxyglutarate (2-HG). IDH mutations are highly prevalent in gliomas.

Ivosidenib, when combined with azacitidine, showed promise in a small, early trial involving patients with IDH1-mutated acute myeloid leukemia, but randomized-trial data were needed. New research ...